Liver disease is either inherited (genetic) or is caused by factors that damage the liver such as viruses (hepatitis A, hepatitis B, and hepatitis C) and excessive alcohol consumption. Obesity is also associated with liver damage. Liver is an essential part of the body, which helps in digestion of food and controls the toxicity of substances in body. Cirrhosis is the result of liver damage, which can be life threatening and can lead to liver failure.
The increasing prevalence of chronic liver diseases such as nonalcoholic fatty liver disease, hepatitis, and others, among large population base in the Middle East region due to lifestyle diseases such as obesity and type 2 diabetes mellitus (DM) and this is expected to drive demand for drugs used in liver disease treatment, thereby propelling the market growth.
Middle East and Turkey chronic liver disease (CLD) therapeutics market size is estimated to be valued at US$ 1,015 million in 2021 and is expected to exhibit a CAGR of 5.8% over the forecast period (2021-2028).
Figure 1. Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market Value (US$ Mn), by Region/Country, 2021
Figure 1.1 Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market Value (US$ Mn), by Region/Country, 2028
|Base Year:||2020||Market Size in 2021:||US$ 1,015 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2021 to 2028|
|Forecast Period 2021 to 2028 CAGR:||5.8%||2028 Value Projection:||US$ 1,500 Mn|
Hoffmann-La Roche AG, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Swedish Orphan Biovitrum AB, GlaxoSmithKline Plc, Sanofi S.A, Merck & Co., Inc., AbbVie Inc., Abbott Laboratories, AstraZeneca plc., and Pfizer Inc.
|Restraints & Challenges:||
Figure 2. Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market Share (%), by Drug Class, 2021
Figure 2.1. Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market Share (%), by Drug Class, 2028
Chemotherapy Drugs segment is expected to hold largest market share in the Middle East and Turkey chronic liver disease (CLD) therapeutics market
Since cancer cells grow and multiply much faster than most of the cells in body, chemotherapy is most often utilized for cancer treatment. The increasing incidence of liver cancer and launch of novel products for cancer treatment are some of the factors, which are expected to drive the Chemotherapy Drugs segment growth. According to the International Agency for Research on Cancer (IARC), age-standardized incidence rate (ASIR) for liver cancer was 4.5 per 100,000 people in 2018 in Saudi Arabia.
Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market Restraint
High cost of treatment for chronic liver diseases is a major factor, which is expected to hinder the market growth. Furthermore, owing to this factor, a large patient pool suffering from CLD is unable to avail proper treatment. The treatment for chronic liver diseases include chemotherapy, targeted therapy, vaccines, immunoglobulin, and others, which are overpriced for the patients in low and middle income countries in the (Middle East and North Africa) MENA region. For instance, the cost of surgical treatment of liver cancer in Herzliya Medical Center, Israel, is US$ 25,000 and the cost of chemotherapy starts at US$ 3,500.
Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market – Impact of Coronavirus (Covid-19) Pandemic
Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19, as pandemic on March 11, 2020. According to the Coronavirus (COVID-19), Weekly Epidemiological Update by the World Health Organization, over 263,563,622 cases and 5,232,562 deaths due to coronavirus disease (COVID-19) were reported till December 03, 2021, across the globe.
Treatment options for cancer such as chemotherapy can weaken the immune system of cancer patients and increase the risk of getting infected. Hence, people suffering from cancer such as liver cancer are at higher risk of developing serious complications due to COVID-19 infection.
Moreover, healthcare providers are adopting telehealth solutions to conduct their services for patients with severe chronic liver disease while maintaining social distancing to combat COVID-19 pandemic without compromising the health of patients with chronic liver disease. Patients can arrange virtual appointments with their doctors for consultations. Healthcare providers are taking above mentioned measures to reduce the spread of COVID-19 infection.
Furthermore some studies also indicated that, COVID-19 was significantly associated with alcoholic liver damage. Nevertheless, impact of alcohol during COVID-19 within the alcohol consumption and ALD may impact COVID-19 pathogenesis.
Major players operating in the Middle East and Turkey chronic liver disease (CLD) therapeutics market include Hoffmann-La Roche AG, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Swedish Orphan Biovitrum AB, GlaxoSmithKline Plc, Sanofi S.A, Merck & Co., Inc., AbbVie Inc., Abbott Laboratories, AstraZeneca plc, and Pfizer Inc.
Chronic liver disease is associated with the progressive destruction of liver parenchyma for longer period of time (6 months) leading to liver fibrosis and cirrhosis. The main etiology of CLD include alcohol induced liver, hepatitis virus (B, C, and D), hepatocellular carcinoma (HCC), liver cancer, and fatty liver diseases. The treatment for chronic liver diseases include chemotherapy, targeted therapy, vaccines, immunoglobulin, and others. Market players such as IceCure Medical, BioLineRx Ltd., Oramed Pharmaceuticals Inc., and BioLineRx Ltd. are engaged in the development of novel treatment options for CLD.
Middle East and Turkey chronic liver disease therapeutics market is estimated to be valued at US$ 1,015 Mn in 2021 and is expected to reach US$ 1,500 Mn by 2028, exhibiting a CAGR of 5.8% during the forecast period (2021-2028).
The increasing incidence of liver disease, growing geriatric population, Government and non-government awareness programs related to liver disease, and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive the growth of the Middle East and Turkey chronic liver disease therapeutics market over the forecast period.
According to National Library of Medicine, in the Middle East, the prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing, with associated risk factors including Obesity, and type 2 Diabetes. The patient’s progress to develop Nonalcoholic Steatohepatitis (NASH) is about 20% to 30%. Younossi, a nationally recognized leader specializing in hepatology and gastroenterology, reported that in Middle East the prevalence to be highest (33%) in a meta-analysis on Global Epidemiology of NAFLD. Awareness with suspected NAFLD has increased over last two decades, but 95% of the patients are still unaware about having liver disease.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.View All Our Clients